Loading organizations...
§ Private Profile · Leuven, Vlaams-Brabant, Belgium
Biotechnology company developing selective HDAC6 inhibitors for neuromuscular, neurodegenerative, cardiometabolic diseases.
Augustine Therapeutics is a Leuven, Belgium-based biotechnology company that develops selective HDAC6 inhibitors for the treatment of severe neurological, neuromuscular, and cardiometabolic diseases. The organization focuses on discovering non-hydroxamate and non-hydrazine drug candidates designed to halt or reverse axonopathies such as Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis. By advancing peripherally-restricted and central nervous system-penetrant inhibitors, the pipeline avoids toxicity risks like genotoxicity while preserving beneficial enzymatic functions. In May 2024, the enterprise secured €17 million in a Series A funding round to advance its lead inhibitor candidate, AGT100216, into first-in-human clinical trials. This financing was led by Asabys Partners and included strategic participation from Eli Lilly and Company, alongside support from the Flanders Institute for Biotechnology. Augustine Therapeutics was founded in 2019 as a spin-off from KU Leuven by scientific founder Ludo Van Den Bosch and Sylvain Celanire.
Augustine Therapeutics has raised $114.3M across 3 funding rounds.
Augustine Therapeutics has raised $114.3M in total across 3 funding rounds.
Augustine Therapeutics has raised $114.3M in total across 3 funding rounds.
Augustine Therapeutics's investors include Clara Campàs, Annette Clancy, Marie Schroeder, Asabys Partners.
Augustine Therapeutics has raised $114.3M across 3 funding rounds. Most recently, it raised $91.4M Series A in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 24, 2025 | $91.4M Series A | Clara Campàs, Annette Clancy, Marie Schroeder | — | Announced |
| Jun 26, 2024 | $18.2M Series A | Asabys Partners | — | Announced |
| Dec 16, 2019 | $4.7M Seed | — | — | Announced |